ChristopherJLesarMD

PubMed

• 2 citations
  Infrarenal Infected Aneurysm of Abdominal Aorta Caused by Clostridium Perfringens
  Laura M. Sherwood, Homer Keadle, Christopher Lesar, W. Heath Giles
  The American Surgeon. 2017-02-01
• 11 citations
  Permissive Hypertension during Awake Eversion Carotid Endarterectomy: A Physiologic Approach for Cerebral Protection
  Christopher Lesar, L. Richard Sprouse, William B. Harris
  Journal of the American College of Surgeons. 2014-04-01
• 79 citations
  Comparison of covered stents versus bare metal stents for treatment of chronic atherosclerotic mesenteric arterial disease
  Gustavo S. Oderich, Luke S. Erdoes, Christopher Lesar, Bernardo C. Mendes, Peter Gloviczki
  Journal of Vascular Surgery. 2012-06-01

Journal Articles

• The size of the expressed HIV reservoir predicts timing of viral rebound after treatment interruption  
  Li JZ, Etemad B, Ahmed H, Aga E, Bosch RJ, Mellors JW, Kuritzkes DR, Lederman MM, Para M, Gandhi RT, AIDS, 1/28/2016
• Relationship Among Viral Load Outcomes in HIV Treatment Interruption Trials  
  Treasure GC, Aga E, Bosch RJ, Mellors JW, Kuritzkes DR, Para M, Gandhi RT, Li JZ., J Acquir Immune Defic Syndr, 1/20/2016
• StudySearch: a web-based application for posting and searching clinical research studies  
  Gonsenhauser B, Hallarn R, Carpenter D, Para MF, Reider CR, J Investig Med, 1/1/2016
• Comparison of the metabolic effects of ritonavir-boosted darunavir or atazanavir versus raltegravir, and the impact of ritonavir plasma exposure: ACTG 5257  
  Ofotokun I, Na LH, Landovitz RJ, Ribaudo HJ, McComsey GA, Godfrey C, Aweeka F, Cohn SE, Sagar M, Kuritzkes DR, Brown TT, Patterson KB, Para MF, Leavitt RY, Villasis-Ke..., Clin Infect Dis, 1/15/2015
• Impact of chemotherapy for HIV-1 related lymphoma on residual viremia and cellular HIV-1 DNA in patients on suppressive antiretroviral therapy  
  Cillo AR, Krishnan S, McMahon DK, Mitsuyasu RT, Para MF, Mellors JW, PLoS One, 1/17/2014
• Polymorphism in glutamate cysteine ligase catalytic subunit (GCLC) is associated with sulfamethoxazole-induced hypersensitivity in HIV/AIDS patients  
  Wang Danxin, Curtis Amanda, Papp C Audrey, Koletar L Susan, Para F Michael, BMC Medical Genomics, 1/1/2013
• The Design of Single-Arm Clinical Trials of Combination Antiretroviral Regimens for Treatment-Naïve HIV-Infected Patients  
  Zheng, S, Eron J, Para, M, Taiwo B, Rosencranz S., IDS Res Hum Retroviruses., 1/1/2013
• HIV and Asthma, Is there an Association  
  Kynyk JA, Parsons JP,1, Para MF, Susan L Koletar SL, Diaz PT, Mastronarde JG, Respir Med, 1/1/2012
• Human N-acetyltransferase 1 10 and 11 alleles increase protein expression through distinct mechanisms and associate with sulfamethoxazole-induced hypersensitivity  
  Wang D, Para MF, Koletar SL, Sadee W, Pharmacogenet Genomics., 1/1/2011
• No evidence for decay in the latent reservoir in HIV infects patients receiving intensive enfuvirdtide- containing antiretroviral therapy  
  Gandhi R, Bosch RJ, Aga E, Albrecht M, Adams E, Demeter L, Dykes C, Bastow B, Para, M, Si;iciano R, Siliciano J, Eron J, for the ACTG 5173 Team., J Infect Dis, 1/15/2010
• Phase I/II Trial of the Anti-HIV Activity of Mifepristone in HIV-infected Subjects ACTG 5200  
  Para MF, Schouten J, Rosenkranz SL, Yu S, Weiner D, Tebas P, White CJ, Reeds D, Lertor J, Patterson K, Daar ES, Cavert W, Brizz B, the ACTG 5200 team., J Acquir Immune Defic Syndr, 1/1/2010
• HIV testing outside of the study among men who have sex with men participating in an HIV vaccine efficacy trial  
  Gust DA, Wiegand RE, Para M, Chen R, Bartholow BN., J Acquir Immune Defic Syndr, 1/1/2009
• Safety, pharmacokinetics and antiviral activity of HGS004, a novel fully human IgG4 monoclonal antibody against CCR5, in HIV-1 infected  
  Lalezari J, Yadavalli G, Para M, Richmond G, DeJesus E, Brown R, Cai W, Chen C, Zhon J, Novello L., Lerderman M, Subramanian M., J Infect Dis, 1/1/2008
• Pharmacokinetic Interactions between efavirenz and dual protease inhibitors in healthy volunteers Biopharmaceutics and Drug Disposition  
  Ma Qing, Forrest A, Rosenkranz S, Para MF, Yarasheski K, Reichman R, Morse G, ACTG 5043 team., Biopharm Drug Dispos, 1/1/2008
• Antiretroviral drug levels and interactions affect lipid, lipoprotein and glucose metabolism in HIV-1 seronegative subjects: A pharmacokinetic- pharmacodynamic analysis  
  Rosenkranz SL,Yarasheski KE, Para MF, Reichman R, Morse GD, and the ACTG 5043 Protocol Team., Metabolic Syndrome and Related Conditions, 1/1/2007
• Compartmental Pharmacokinetic Analysis of Oral Amprenavir with Secondary Peak  
  Okusanya O, Forrest A, DiFrancesco R, Balic S, Rosenkranz S, Para MF, Adams E, Yarasheski KE, Reichman RC, Morse GD., Antimicro Agent Chemo., 1/1/2007
• Partner-specific sexual behavioral differences between phase 3 HIV vaccine efficacy trial participants and controls: Project VISION  
  Whittington WL, Morris M, Buchbinder SP, McKirnan DJ, Mayer KH, Para MF, Bartholow BN, Celum CL, J Acquir Immune Defic Syndr., 1/1/2006
• Third Trimester Maternal Toxicity with Nevirapine use in Pregnancy  
  Joy S, Poi M, Hughes L, Brady M, Koletar, SL, Para MF, and Fan-Havard, P, Obstet and Gynecol, 1/1/2005
• Amprenavir and Efavirenz Pharmacokinetics Before and After the Addition of Nelfinavir, Indinavir, Ritonavir or Saquinavir Antimicrob  
  Morse GD, Rosenkranz S, Para MF, Segal Y DiFrancesco R Adams E Brizz B, Yarasheski K, Reichman R, and the ACTG 5043 Protocol Team, Agents Chemother., 1/1/2005
• Placebo-controlled trial of a recombinant glycoprotein 120 vaccine to prevent HIV infection  
  Gurwith,M, Gilbert P, Berman P, Flynn, N, Forthal D, Harro C, Heyward, W, Hudgens M, Judson F, Mayer K, Metch B, Para, MF, PopovicV, Self, S., and Francis DP, for the ..., J Infect Dis, 1/1/2005
• Population pharmacokinetics of delavirdine and N-delavirdine in HIV-infected individuals  
  Smith PF, DiCenzo R, Forrest A, Shelton M, Friedland G, Michael F. Para MF, Pollard R, Fischl M, DiFrancesco R, Morse GD, Clinical Pharmacokinet, 1/1/2005
• HIV Sexual Risk Behavior over 36-Months of Follow-up in the World's First HIV Vaccine Efficacy Trial  
  Bartholow, Buchbinder S, Celum C, Goli V, Koblin B, Para M, Marmor M, Novak RM, Mayer K, McKirnan DJ, Creticos C, Orozco-Cronin P, Popovic V, and Mastro TD, for the VI..., BN J Acquir Immune Defic Syndr, 1/1/2005
• Drug rash, eosinophilia, systemic syndrome and renal toxicity with nevirapine-containing regimen in a pregnant patient with HIV  
  Knudtson E, Para M, Boswell H, and Fan-Havard P., Obstet Gynecol, 1/1/2003
• Virologic and CD4 cell response to zidovudine or zidovudine and lamivudine following didanosine treatment of human immunodeficiency virus infection  
  Katzenstein DA, Hughes MD, Albrecht M, Liou SH, Murphy R, Balfour H, Para M, Hammer S, AIDS Res Hum Retroviruses, 1/10/2001
• Virologic efficacy of nelfinavir and/or efavirenz with new nucleoside therapy in HIV-infected individuals with prior nucleoside analog exposure  
  Albrecht MA, Bosch RJ, Dehlinger M, Katzenstein DA, Liou SH, Eron J, Para MF, Valdez H, Kessler H, Hammer SM, N Engl J Med, 1/9/2001
• Join now to see all

Books/Book Chapters

• Antimicrobial Therapy and Vaccines Volume II Antimicrobial Agents 
  Chapter: Nonnucleoside Analogue Reverse Transcriptase Inhibitors 
  Fletcher C, Swindells S, Para M.Editors: Yu V, Edwards G, McKinnon P, Peloquin, Morse, Potoski.2005
• Principals of Infection and Resistance 
  Chapter: Immunizations 
  Page 289 - 304Koletar SL and Para MFEditors: Mortensen RF, Krier J.Harper and Rowe Publishers, Philadelphia, PA1990
• Internal Medicine - Case studies. 
  Chapter: A man with shortness of breath, weight loss and night sweats 
  Page 16 - 32Para MFEditors: Bowen & Mazzaferri.Plenum Publishing, New York, NY1989
• Mitral Valve Prolapse and Mitral Valve Prolapse Syndrome 
  Chapter: Mitral Valve Prolapse and Infective Endocarditis 
  Page 275 - 288Koletar SL and Para MFEditors: Boudoulas, H. and Wooley, C..Futura Publishing Co., Mount Kisco, N.Y.1988
• Sexually Trans­mitted Diseases 
  Chapter: Genital ulcer syndrome 
  Page 161 - 185Para MF and Baird IEditors: R. Prior and V. Spagna.Marcel Dekker, New York, NY1985
• Legionella, Proceedings of the Second Inter­national Symposium on Legionella 
  Chapter: Production of monoclonal anti­bodies to Legionella pneumophila and the relationship of monoclonal antibody binding to plasmid content 
  Page 262 - 264Para MF, Plouffe JF and Maher WEEditors: Thornsberry C., Balows A, Feeley JC, Jakubowski W.ASM Publications, Washington, D.C.1984
• Legionella, Proceedings of the Second International Symposium on Legionella 
  Chapter: Nosocomial Le­gionnaires' disease: Difference in attack rates associated with two strains of Legionella pneumophila serogroup l. 
  Page 216 - 218Plouffe JF, Para MF, Hackman B, Webster L, Maher WEEditors: Thornsberry C, Balows, Feeley JC, Jakubowski W.ASM Publications, Washington, D.C.1984
• Legionella, Pro­ceedings of the Second International Symposium on Legionella 
  Chapter: Plasmid profiles of clinical and environmental isolates of serogroup 1 Legionella pneumophila. 
  Page 272 - 274Maher WE, Plouffe JF, Para MFEditors: Thornsberry C, Balows A, Feeley JC, Jakubowski W.ASM Publications, Washington, D.C.1984
• Les Infections 
  Chapter: Encephalitis and parameningeal infection 
  Page 589 - 605Para MF, and Gardner PEditors: Jean-Claude Pechere.Edisem, St. Hyacinthe, Quebec1983
• Recent Advances in Clinical Therapeutics: Antivirals and Antimicrobials, Anticancer Agents 
  Chapter: Newer antiviral agents 
  Page 57 - 70Para MFGrune & Stratton, Inc., San Diego, CA1983
• The Human Herpesviruses: Interdisciplinary perspective. 
  Chapter: The Fc binding receptor induced by herpes simplex virus 
  Page 237 - 241Spear PG, Para MF, Baucke REditors: A.J. Nahmias, W.R. Dowdle, R. Schinazi.Elsevier North Holland, Inc.1981
• Join now to see all

Other

• Understanding HIV Infection 
  Para MF, Audio Digest, Internal Medicine
  1/19/1990
• Computer Assisted Instruction - AIDS Clinical Vignettes for Physicians 
  Para MF, Health Sciences Consortium
  Ohio State University College of Medicine - 1/1/1988